Monitor APOLLO topline data in Q4 2026 and RESTORE-PV initial data in Q3 2026 as key catalysts. The FDA alignment reduces regulatory risk for bitopertin, and the accelerated enrollment timeline for DISC-3405 suggests strong investigator interest. Cash runway into 2029 provides ample funding through these milestones.
Price Chart
Executive Summary
Disc Medicine reported Q2 2026 net loss of $59.5M ($1.54/share), beating consensus of -$1.77 by 13%. The key catalyst is the completed Type A FDA meeting aligning that the Phase 3 APOLLO trial of bitopertin in EPP, if successful, can serve as the basis for a CRL response, with topline data expected in Q4 2026. The company also completed enrollment for the RESTORE-PV Phase 2 study of DISC-3405, with initial data now expected in Q3 2026, ahead of schedule.
Key Financial Metrics
Key Facts
- Q2 2026 net loss of $59.5M ($1.54/share) vs $55.2M ($1.58/share) in Q2 2025, beating consensus of -$1.77
- Cash, cash equivalents, and marketable securities of $717.7M as of June 30, 2026, providing runway into 2029
- Completed Type A meeting with FDA; Phase 3 APOLLO topline data for bitopertin in EPP expected Q4 2026
- Completed enrollment for RESTORE-PV Phase 2 study of DISC-3405 in polycythemia vera; initial data expected Q3 2026
- Selcodebart (DISC-0974) received EU Orphan Drug Designation for myelofibrosis; updated RALLY-MF data presented at ASCO/EHA
Financial Impact
Net loss of $59.5M in Q2 2026, slightly wider than $55.2M in Q2 2025; cash burn rate consistent with prior quarter
Risk Factors
- Phase 3 APOLLO trial failure would significantly impair bitopertin's regulatory path
- Clinical-stage biotech with no approved products or revenue; relies on successful pipeline advancement
- Cash burn rate may increase as multiple programs advance into later-stage trials
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3336047 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $74.14 $69.18 | ▼ −6.69% | ▼ −6.19% | $64.48 (−13.03%) |
Sep 9, 2026 22d ago | Press Release | $74.14 $69.18 | ▼ −6.69% | ▼ −6.19% | $64.48 (−13.03%) |
Sep 3, 2026 28d ago | Insider Cluster | $79.23 $68.92 | ▲ +13.01% | ▲ +11.80% | $64.48 (+18.62%) |
Sep 2, 2026 29d ago | 144 | $79.37 $70.06 | ▼ −11.73% | ▼ −10.58% | $64.48 (−18.76%) |
Aug 27, 2026 5w ago | Insider Cluster | $82.55 $79.37 | ▼ −3.85% | ▼ −4.12% | $64.48 (−21.89%) |
Aug 18, 2026 6w ago | Insider Cluster | $80.32 $82.67 | ▲ +2.93% | ▲ +3.31% | $64.48 (−19.72%) |
Aug 14, 2026 6w ago | Insider Cluster | $80.05 $80.94 | ▲ +1.11% | ▲ +2.30% | $64.48 (−19.45%) |
Jul 30, 2026 9w ago | 8-K | $79.21 $77.44 | ▼ −2.23% | ▼ −5.86% | $64.48 (−18.60%) |
Jul 30, 2026 9w ago | Press Release | $79.21 $77.44 | ▼ −2.23% | ▼ −5.86% | $64.48 (−18.60%) |
Jul 14, 2026 11w ago | Insider Cluster | $76.02 $74.32 | ▼ −2.24% | ▼ −1.26% | $64.48 (−15.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access